Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Acquisitions & Divestments: 2015-2024

Historic Change in Acquisitions & Divestments for ImmunityBio (IBRX) over the last 10 years, with Dec 2024 value amounting to $115.6 million.

  • ImmunityBio's Change in Acquisitions & Divestments fell 58.91% to $5.3 million in Q1 2025 from the same period last year, while for Mar 2025 it was $107.9 million, marking a year-over-year increase of 184.92%. This contributed to the annual value of $115.6 million for FY2024, which is 1044.42% up from last year.
  • As of FY2024, ImmunityBio's Change in Acquisitions & Divestments stood at $115.6 million, which was up 1,044.42% from $10.1 million recorded in FY2023.
  • ImmunityBio's Change in Acquisitions & Divestments' 5-year high stood at $128.2 million during FY2022, with a 5-year trough of $10.1 million in FY2023.
  • In the last 3 years, ImmunityBio's Change in Acquisitions & Divestments had a median value of $115.6 million in 2024 and averaged $84.6 million.
  • Per our database at Business Quant, ImmunityBio's Change in Acquisitions & Divestments crashed by 92.12% in 2023 and then surged by 1,044.42% in 2024.
  • ImmunityBio's Change in Acquisitions & Divestments (Yearly) stood at $65.3 million in 2020, then decreased by 14.05% to $56.2 million in 2021, then soared by 128.23% to $128.2 million in 2022, then crashed by 92.12% to $10.1 million in 2023, then spiked by 1,044.42% to $115.6 million in 2024.